These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
618 related articles for article (PubMed ID: 32149732)
1. Immunotherapy of multiple myeloma. Minnie SA; Hill GR J Clin Invest; 2020 Apr; 130(4):1565-1575. PubMed ID: 32149732 [TBL] [Abstract][Full Text] [Related]
2. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy? Minnie SA; Hill GR Front Immunol; 2021; 12():651288. PubMed ID: 33777050 [TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. Chung C Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103 [TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy. Rocchi S; Zannetti BA; Marconi G; Lanza F Cells; 2024 May; 13(10):. PubMed ID: 38786075 [TBL] [Abstract][Full Text] [Related]
6. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma. Podar K; Jager D Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977 [TBL] [Abstract][Full Text] [Related]
7. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Ye R; Kundrapu S; Gerson SL; Driscoll JJ; Beck R; Ali N; Landgren O; VanHeeckeren W; Luo G; Kroger N; Caimi P; De Lima M; Malek E Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e213-e220. PubMed ID: 30878316 [TBL] [Abstract][Full Text] [Related]
8. Current developments in immunotherapy in the treatment of multiple myeloma. Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124 [TBL] [Abstract][Full Text] [Related]
9. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219 [TBL] [Abstract][Full Text] [Related]
10. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947 [TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333 [TBL] [Abstract][Full Text] [Related]
12. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. Garderet L; Morris C; Beksac M; Gahrton G; Schönland S; Yakoub-Agha I; Hayden PJ Biol Blood Marrow Transplant; 2020 Sep; 26(9):1559-1566. PubMed ID: 32417491 [TBL] [Abstract][Full Text] [Related]
13. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Tai YT; Cho SF; Anderson KC Front Immunol; 2018; 9():1822. PubMed ID: 30147691 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. Castella M; Fernández de Larrea C; Martín-Antonio B Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802 [TBL] [Abstract][Full Text] [Related]
15. Myeloma-Secreted Galectin-1 Potently Interacts with CD304 on Monocytic Myeloid-Derived Suppressor Cells. Lim JY; Kim TW; Ryu DB; Park SS; Lee SE; Kim BS; Min CK Cancer Immunol Res; 2021 May; 9(5):503-513. PubMed ID: 33771821 [TBL] [Abstract][Full Text] [Related]
17. Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma. Janakiram M; Arora N; Bachanova V; Miller JS Transplant Cell Ther; 2022 Feb; 28(2):61-69. PubMed ID: 34634499 [TBL] [Abstract][Full Text] [Related]
18. [The guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)]. ; ; Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):341-346. PubMed ID: 32370461 [TBL] [Abstract][Full Text] [Related]
19. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. Yousef S; Heise J; Lajmi N; Bartels K; Kröger N; Luetkens T; Atanackovic D J Transl Med; 2015 Jun; 13():197. PubMed ID: 26088750 [TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]